Figure 2 | Scientific Reports

Figure 2

From: TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin

Figure 2

Synergistic effect of AF-TUSC2-erlotinib combination.

(A,B) Wild type EGFR TUSC2 Tet-On stable clones H157 and H1299 were treated with 1 μg/ml doxycycline (TUSC2 expression); 2.3 μM erlotinib; 0.5 μM auranofin; 1 μg/ml doxycycline/2.3 μM erlotinib; 1 μg/ml doxycycline/0.5 μM Auranofin; 2.3 μM erlotinib/0.5 μM Auranofin; and 1 μg/ml doxycycline/1 μg/ml doxycycline and 0.5 μM auranofin for 72 hours. Untreated cells were used as control. Cell viability was assessed with XTT assay. After adjusting for multiple comparisons, a significant inhibitory effect was found for the TUSC2-erlotinib-AF combination compared to any other treatment using three-way ANOVA and two-tailed t test. Data shown represent the mean ± SE of three independent experiments. (C,D) Loewe additivity model was used at 95% confidence intervals (CI); II < 1, II = 1, and II > 1 correspond to the drug interactions’ being synergistic, additive, and antagonistic, respectively. Blue needles represent synergy; Grey represents combination of the three drugs that had interaction index (II) less than one without synergy; Black represents combination of the three drugs with an interaction index (II) above one without antagonism; Red and green surface represent antagonistic and additive effects respectively.

Back to article page